Last reviewed · How we verify
Mayinglong Musk Hemorrhoid Ointment
Mayinglong Musk Hemorrhoid Ointment, marketed by Xian-Janssen Pharmaceutical Ltd., is an established treatment for hemorrhoids with a key composition patent expiring in 2028. The ointment's market position is bolstered by its long-standing presence and recognized efficacy, though specific revenue figures are not disclosed. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Mayinglong Musk Hemorrhoid Ointment |
|---|---|
| Sponsor | Xian-Janssen Pharmaceutical Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: